SSY GROUP (02005): Medical recombinant collagen peptide gynecological gel and B-type natriuretic peptide (BNP) detection kit (fluorescence immunochromatography method) has been awarded a medical device registration certificate by the Hebei Food and Drug Administration.

16:33 27/02/2026

ShiSiYao Group (02005) announced that the medical recombination collagen gel for gynecology and the B-type natriuretic peptide (BNP) test kit (fluorescence immunochromatographic method) of this Group have obtained the medical device registration certificate issued by the Hebei Provincial Drug Administration.

SSY GROUP (02005) announced that two medical devices, medical recombinant collagen gynecological gel and B-type natriuretic peptide (BNP) detection reagent kit (fluorescent immunoassay), have obtained the medical device registration certificate from the Hebei Provincial Drug Administration of China. The medical recombinant collagen gynecological gel is mainly used to prevent the colonization of pathogenic microorganisms on the vaginal wall. The B-type natriuretic peptide (BNP) detection reagent kit is mainly used for in vitro quantitative determination of the content of B-type natriuretic peptide (BNP) in human plasma and whole blood samples as an auxiliary diagnostic risk assessment for heart failure.

WAI CHUN BIOTEC (00660) releases its interim performance, with a net loss attributable to shareholders of HK$5.939 million, a decrease of 56.53% compared to the same period last year.

China Motor Bus (00026) released its interim results, with a post-tax loss attributable to shareholders of HK$64.404 million, representing an 88.29% increase year-on-year.

HAOHAI BIOTEC (06826) is expected to have a net profit attributable to the parent company of approximately 2.51 billion yuan in 2025, a decrease of 40.3% year-on-year.

WAI CHUN BIOTEC (00660) releases its interim performance, with a net loss attributable to shareholders of HK$5.939 million, a decrease of 56.53% compared to the same period last year.

China Motor Bus (00026) released its interim results, with a post-tax loss attributable to shareholders of HK$64.404 million, representing an 88.29% increase year-on-year.

HAOHAI BIOTEC (06826) is expected to have a net profit attributable to the parent company of approximately 2.51 billion yuan in 2025, a decrease of 40.3% year-on-year.